Indication
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
1 clinical trial
1 product
Clinical trial
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 12 Weeks of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Status: Recruiting, Estimated PCD: 2027-10-11
Product
Tolvaptan